🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

He Huang clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with He Huang as lead sponsor. Synced 26 Sep 2026
11Current trials
9Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

He Huang is the lead sponsor of 11 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are JY231, Busulfan and Cyclophosphamide. The most-studied condition is Hematologic Diseases.

ClinicalTrials.gov trials by status

  • Recruiting982%
  • Not yet open218%

Trials by phase

  • Phase EARLY_PHASE1436%
  • Phase 1327%
  • Not applicable327%
  • Phase 419%
01

Clinical trials sponsored by He Huang

11 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809699 · ClinicalTrials.gov ↗ · Hematologic Diseases
Phase 1 Recruiting 2022-08 China
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
NCT04227015 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Phase EARLY_PHASE1 Recruiting 2020-01 China
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
NCT04283006 · ClinicalTrials.gov ↗ · Relapsed and Refractory, Lymphoid Hematological Malignancies
Phase EARLY_PHASE1 Recruiting 2018-05 China
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
NCT06162338 · ClinicalTrials.gov ↗ · Gaucher Disease Type I
Not applicable Recruiting 2023-11 China
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
NCT06785519 · ClinicalTrials.gov ↗ · Lupus Nephritis
Phase EARLY_PHASE1 Recruiting 2025-01 China
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
NCT06084962 · ClinicalTrials.gov ↗ · Relapse/Refractory Multiple Myeloma
Phase 1 Recruiting 2023-10 China
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT06571825 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
Phase 4 Recruiting 2024-07 China
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NCT06120166 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma
Phase EARLY_PHASE1 Recruiting 2023-11 China
Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation
NCT06809712 · ClinicalTrials.gov ↗ · Hematologic Disease
Phase 1 Recruiting 2022-08 China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
NCT06879470 · ClinicalTrials.gov ↗ · B-Non Hodgkin Lymphoma
Drug: JY231
Not applicable Not yet open 2025-03 China
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
NCT06902025 · ClinicalTrials.gov ↗ · B-ALL
Drug: JY231
Not applicable Not yet open 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in He Huang trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in He Huang trials

13 conditions
Hematologic Diseases1Acute Lymphoblastic Leukemia1Non-hodgkin Lymphoma1Relapsed and Refractory1Lymphoid Hematological Malignancies1Gaucher Disease Type I1Lupus Nephritis1Relapse/Refractory Multiple Myeloma1B-Non Hodgkin Lymphoma1Acute Myeloid Leukemia1B-ALL1Diffuse Large B-cell Lymphoma1Hematologic Disease1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China119

A trial with sites in more than one country appears in each of those registers.

05

Questions about He Huang trials

How many clinical trials does He Huang sponsor?

He Huang is the lead sponsor of 11 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are He Huang trials recruiting?

Yes. 9 of its 11 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is He Huang testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are JY231 (2), Busulfan (1), Cyclophosphamide (1), Fludara (1) and Fludarabine (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.